The Quantellect read.As of Nov 19, 2026, 13 active firms cover Dyne Therapeutics Inc: 11 rate it Buy or better, 1 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. The target range is very wide, $10.00 to $47.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $32.27 sits 103% above the current $15.88. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.00 next quarter toward $-3.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy1185%
Neutral18%
Sell18%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$32.27
+103.2% upside
Average target across 11 active firms as of Nov 19, 2026 vs $15.88 current
Highest Target$47.00
Average Target$32.27
Lowest Target$10.00
Detailed analyst forecasts for DYN
Showing 1–13 of 13 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 11 of 13 active firms rate DYN a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DYN EPS & revenue forecast
EPS · NEXT QUARTER
$-1.00
Range $-1.08 – $-0.91 · 6 analysts · +37% YoY
Next period, 6 analysts expect Dyne Therapeutics Inc to earn $-1.00 a share (range $-1.08 – $-0.91), versus $-0.73 a year earlier. Full-year consensus is $-3.91, growing to $-3.55 the year after.
REVENUE · NEXT QUARTER
$3.0M
Range $125.0K – $9.0M · 6 analysts
Revenue is expected to reach $3.0M (range $125.0K – $9.0M). Full-year consensus is $0, rising to $54.3M next year.
Top analysts covering Dyne Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DYN.
#1
Luca Issi
RBC Capital · Rank #76
Buy
$30.00+88.9% to target
Overall win rate
49%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Buy
$38.00+139.3% to target
Overall win rate
41%
+ Follow
#3
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$50.00+214.9% to target
Overall win rate
39%
+ Follow
#4
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$40.00+151.9% to target
Overall win rate
41%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$47.00+196.0% to target
Overall win rate
29%
+ Follow
DYN stock forecast FAQ
What is DYN's average 12-month price target?+
The 11 active firms with a live target average $32.27 for Dyne Therapeutics Inc over the next 12 months, ranging from a $47.00 high to a $10.00 low, as of Nov 19, 2026.
Is DYN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 11 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DYN?+
The Street-high target is $47.00 (Piper Sandler), and the Street-low is $10.00 (JP Morgan). The average of all 11 active-firm targets is $32.27.
How many active Wall Street firms cover DYN?+
13 active firms have a recognized rating on Dyne Therapeutics Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DYN?+
Among analysts who currently cover DYN, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Buy with a $30.00 target.
What is Dyne Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.00 per share (range $-1.08 – $-0.91) across 6 analysts. Full-year EPS is projected at $-3.91, rising to $-3.55 the following year.
How much revenue is Dyne Therapeutics Inc expected to report next quarter?+
Consensus revenue is $3.0M (range $125.0K – $9.0M). Full-year revenue is projected at $0, growing to $54.3M next year.
Have analysts been upgrading or downgrading DYN lately?+
As of Nov 19, 2026, 11 of 13 active firms rate DYN a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DYN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.